Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

被引：0
|
作者：
Tingli Guo
Wenhui Yan
Xin Cui
Na Liu
Xiaotong Wei
Yuzhuo Sun
KeXin Fan
Jieyun Liu
Yuanyuan Zhu
Zhuanzhuan Wang
Yilei Zhang
Lina Chen
机构：
[1] Xi’an Jiaotong University Health Science Center,Department of Pharmacology, School of Basic Medical Sciences
[2] Xi’an Jiaotong University Health Science Center,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, The Institute of Molecular and Translational Medicine
[3] Translational Medicine Institute,Institute of Cardiovascular Sciences
[4] Xi’an Jiaotong University Health Science Center,Key Laboratory of Environment and Genes Related to Diseases
[5] Xi’an Jiaotong University,Department of Endocrinology
[6] Ministry of Education,Department of Thoracic Surgery
[7] The First Affiliated Hospital of Xi’an Jiaotong University,undefined
[8] The First Affiliated Hospital of Xi’an Jiaotong University,undefined
来源：
Molecular Medicine | / 29卷
关键词：
Liraglutide; Type 2 diabetes mellitus; Non-alcoholic fatty liver disease; Lipid peroxidation; Ferroptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
    Guo, Tingli
    Yan, Wenhui
    Cui, Xin
    Liu, Na
    Wei, Xiaotong
    Sun, Yuzhuo
    Fan, Kexin
    Liu, Jieyun
    Zhu, Yuanyuan
    Wang, Zhuanzhuan
    Zhang, Yilei
    Chen, Lina
    MOLECULAR MEDICINE, 2023, 29 (01)
  • [2] Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
    Tian, Feng
    Zheng, Zhigang
    Zhang, Damin
    He, Si
    Shen, Jie
    BIOSCIENCE REPORTS, 2018, 38
  • [3] Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
    Koullias, Emmanouil S.
    Koskinas, John
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (05) : 965 - 971
  • [4] Non-alcoholic fatty liver disease and type 2 diabetes mellitus
    Par Alajos
    Wittmann Istvan
    Par Gabriella
    ORVOSI HETILAP, 2022, 163 (21) : 815 - 825
  • [5] Non-alcoholic fatty liver disease and type 2 diabetes mellitus
    Par Alajos
    Wittmann Istvan
    Par Gabriella
    ORVOSI HETILAP, 2022, 163 (22) : 855 - 862
  • [6] The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus
    Heyens, Leen
    Robaeys, Geert
    Bielen, Rob
    Kockaerts, Yves
    Busschots, Dana
    JOURNAL OF HEPATOLOGY, 2020, 73 : S412 - S413
  • [7] Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Resuli, B.
    Agaci, F.
    Kraja, B.
    Sema, K.
    Dhigoi, N.
    Kapia, M.
    Burda, I.
    DIABETOLOGIA, 2010, 53
  • [8] The Effectiveness of Liraglutide in Non-alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
    Ohki, Takamasa
    Akihiro, Isogawa
    Ooga, Takafumi
    Sato, Koki
    Fujiwara, Hiroaki
    Seki, Michiharu
    Toda, Nobuo
    Tagawa, Kazumi
    HEPATOLOGY, 2012, 56 : 906A - 906A
  • [9] Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of type 2 diabetes mellitus
    Loosen, Sven H.
    Luedde, Tom
    Roderburg, Christoph
    JOURNAL OF HEPATOLOGY, 2023, 78 : S630 - S631
  • [10] Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
    Khneizer, Gebran
    Rizvi, Syed
    Gawrieh, Samer
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 417 - 440
12345